M1Pram in the spotlight in the April “Diabetes, Obesity and Metabolism” Edition

The scientific journal “Diabetes, Obesity and metabolism” has selected and published ADOCIA’s cover page and article dedicated to its product M1Pram (ADO09):

“ADO09, a co‐formulation of the amylin analogue pramlintide and the insulin analogue A21G, lowers postprandial blood glucose versus insulin lispro in type 1 diabetes”;

Grit Andersen MD, Grégory Meiffren PhD, Susanne Famulla PhD, Tim Heise MD, Aymeric Ranson MSc, Cyril Seroussi MSc, Rosy Eloy MD, Martin Gaudier PhD, Richard Charvet PhD, You‐Ping Chan PhD, Olivier Soula PhD, J. Hans DeVries MD.

Diabetes, Obesity and Metabolism, Volume 23, Issue 4: Link to the article

Adocia is honored to offer the cover page illustrating the M1Pram co-formulation of insulin and amylin for the treatment of patients living with type 1 and type 2 diabetes.

Thanks to Adocia and Profil’s researchers, who are leading this ambitious and innovative project using bi-hormonal formulations dedicated to diabetes treatments.